Gritstone Oncology Inc (GRTS)

Gritstone Oncology Stock Analysis & Ratings

GRTS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.71 - $14.42
Previous Close$2.46
Average Volume (3M)1.34M
Market CapN/A
Enterprise ValueN/A
P/E Ratio-1.7
Next EarningsAug 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Gritstone Oncology’s price range in the past 12 months?
Gritstone Oncology lowest stock price was $1.71 and its highest was $14.42 in the past 12 months.
    What is Gritstone Oncology’s market cap?
    Currently, no data Available
    What is Gritstone Oncology’s price target?
    The average price target for Gritstone Oncology is $16.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $20.00 ,the lowest forecast is $12.00. The average price target represents 550.41% Increase from the current price of $2.46.
      What do analysts say about Gritstone Oncology?
      Gritstone Oncology’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is Gritstone Oncology’s upcoming earnings report date?
        Gritstone Oncology’s upcoming earnings report date is Aug 15, 2022 which is in 44 days.
          How were Gritstone Oncology’s earnings last quarter?
          Gritstone Oncology released its earnings results on May 05, 2022. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.367 by $0.027.
            Is Gritstone Oncology overvalued?
            According to Wall Street analysts Gritstone Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Gritstone Oncology pay dividends?
              Gritstone Oncology does not currently pay dividends.
              What is Gritstone Oncology’s EPS estimate?
              Gritstone Oncology’s EPS estimate is -$0.4.
                How many shares outstanding does Gritstone Oncology have?
                Gritstone Oncology has 72,812,836 shares outstanding.
                  What happened to Gritstone Oncology’s price movement after its last earnings report?
                  Gritstone Oncology reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.367. Following the earnings report the stock price went down -7.364%.
                    Which hedge fund is a major shareholder of Gritstone Oncology?
                    Among the largest hedge funds holding Gritstone Oncology’s share is Versant Venture Management, LLC. It holds Gritstone Oncology’s shares valued at 15M.


                      Gritstone Oncology Stock Analysis

                      The Gritstone Oncology stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Gritstone Oncology Inc

                      Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.

                      Similar Stocks
                      Price & Change
                      Rubius Therapeutics
                      Sutro Biopharma
                      Replimune Group
                      Magenta Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis